Pharmaceutical

TerSera’s ZOLADEX LA gains Health Canada approval for breast cancer

TerSera has obtained Health Canada approval for ZOLADEX LA 10.8mg to manage oestrogen receptor-positive (ER+) early breast cancer.

May 9, 2024 - 00:00
TerSera’s ZOLADEX LA gains Health Canada approval for breast cancer
TerSera has obtained Health Canada approval for ZOLADEX LA 10.8mg to manage oestrogen receptor-positive (ER+) early breast cancer.
Read the original article

Tags:

Previous Article

BioVersys and GSK expand their partnership for TB treatment alpibectir

Next Article

Broken String Biosciences teams up with Francis Crick Institute for ALS research

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Adcentrx raises funds to advance ADCs into clinical development

Adcentrx raises funds to advance ADCs into clinical dev...

Apr 26, 2023

STAT+: Drug firms test medicines to halt Alzheimer’s before symptoms appear

STAT+: Drug firms test medicines to halt Alzheimer’s be...

Aug 31, 2023

Rhythm expands obesity portfolio with Phase II weight loss drug for $100m

Rhythm expands obesity portfolio with Phase II weight l...

Jan 5, 2024